Hetero Drugs Limited - The Indian Pharmaceutical … 3 of 30 3 Hetero Drugs Limited Laws Governing...
Transcript of Hetero Drugs Limited - The Indian Pharmaceutical … 3 of 30 3 Hetero Drugs Limited Laws Governing...
Slide 1 of 301
Hetero Drugs Limited
Global Challenges in Quality Assurance of APIs
The Perspective of Indian Manufacturers
Slide 3 of 303
Hetero Drugs Limited
Laws Governing GMPs/Quality
United States – Food, Drugs and Cosmetics Act
Europe – European Pharmaceutical Legislation – GMPs for APIs
India – Drug and Cosmetic Act (Schedule –M –APIs)
Slide 4 of 304
Hetero Drugs Limited
Additional requirements by ICH, adopted by Authorities
ICH Q7
Adoption of Q8, Q9, Q10 Principles to Drug Substance
ICH Q11
Slide 5 of 305
Hetero Drugs Limited
Inspection History In India – The Evolutionary Process
Early 1980s – The Start of FDA Inspections for sites in India
Early 2000s – The start of WHO Inspections
Mid 2000s – The onset of European Inspections, TGA Inspections etc.
Slide 6 of 306
Hetero Drugs Limited
Inspection History In India – The Evolutionary Process
Increased number of API manufacturing facilities with Approvals from Agencies, over the past decade
Success Rates in terms of the inspections of the APIs by Authorities such as USFDA, EU Agencies, EDQM, TGA, etc., reflects the commitment by the API manufacturers to gear up to the continuous changes in the Regulations and their implementation.
Slide 7 of 307
Hetero Drugs Limited
Inspection History In India – The Evolutionary Process
Several Companies from India are part of WHO Pre-Qualification Programme particularly for the Supply of Anti-Retroviral APIs, reflecting the efforts of the API manufacturers to ensure compliance to the Stringent Requirements in terms of Quality and adherence to cGMPs
Slide 8 of 308
Hetero Drugs Limited
Inspection History In India – The Evolutionary Process
The number of the Firms that supply the APIs to the Highly Regulated Markets like US, Canada, Europe, Australia, Japan have increased over the past few years, reflecting the understanding that these organizations have gained on the Laws governing the Supplies of the Pharmaceuticals / APIs in those countries.
Slide 9 of 309
Hetero Drugs Limited
Inspection History In India – The Evolutionary Process
Efforts and steps increased manifold by the Manufacturers to imbibe the philosophy of building in Quality right from the Development of the process to Distribution of the API, minimizing all the risks associated with the manufacture
Slide 10 of 3010
Hetero Drugs Limited
Changes in Inspectional Approaches –Preparedness of Industry
The Approach by the Inspectors adopted by the Inspectors from Different Authorities changed over the period of time, with the stress being on Documentation at some time and on the Practices at some time, ultimately culminating into the Stress on The Quality Management Systems as a whole, thus laying the importance on the Involvement of Top Management of the Firms in implementation and propagation of the current Regulatory Requirements.
Slide 11 of 3011
Hetero Drugs Limited
Changes in Inspectional Approaches –Preparedness of Industry
Thus, the most important aspect in the current Scenario is that the Improvements could be expedited with the decision-making Authorities themselves getting involved, following the systems, within the Regulatory Framework.
Slide 12 of 3012
Hetero Drugs Limited
Regulatory Submissions – Quality Aspects
Changing Approaches to Submissions – Quality of Information /Adequacy
Increased levels of Criticality in Evaluation of process vis-à-vis Specifications
Time-bound review framework – response in time (Particularly the Centralised / Decentralised Procedures approach in the EU)
Slide 13 of 3013
Hetero Drugs Limited
Regulatory Submissions – Quality Aspects
Understanding on Variations – Current Scenario in the US/Europe and other Regulated Markets –Minimizing queries and speedier response, following the right approach ( from development to commercial
Slide 14 of 3014
Hetero Drugs Limited
Regulatory Submissions – Quality Aspects
The Indian API manufacturers are geared up to meet all the current challenges posed w.r.t the review process, of particular importance to mention is the current trend on the queries related to the Impurities of Genotoxic concerns and Definition of Starting Materials
Slide 15 of 3015
Hetero Drugs Limited
Regulatory Submissions – Quality Aspects
Proactive approach in the Choice of the Process, thus optimising the specifications in terms of the Impurities, adoption of the suitable validated methods, use of advanced techniques in Characterisation are the important aspects of current day API Development
Slide 16 of 3016
Hetero Drugs Limited
Emphasis
The Emphasis of API Manufacturers has always been on continuous improvement to meet the changing dynamics of a Regulated Environment
The Primary requirement in this scenario is to have Trained Staff who upgrade by understanding the current Regulations.
Slide 17 of 3017
Hetero Drugs Limited
Emphasis
Periodic Training to all levels of Staff in various functions related to the Manufacture to ensure current Understanding w.r.t. Regulations / Guidances
Periodic Self Audits to ensure compliance to the Quality Systems and initiating the necessary actions to improve the system.
Slide 18 of 3018
Hetero Drugs Limited
Emphasis
Continuously improving upon the Procedures (SOPS), Documentation and Record-keeping is also on of the most important aspect which the Industry is always focused on. Improvement followed by Implementation in addition to constant monitoring and reviews are also part of the current systems being followed.
Slide 19 of 3019
Hetero Drugs Limited
Emphasis
Emphasis is also on learning from past Industry experiences, Inspection Observations, etc., as part of improvement.
Slide 20 of 3020
Hetero Drugs Limited
Operational Challenges vis-à-vis Complexities of API Manufacture - Maintaining the Quality
Facilities ( w.r.t product nature, e.g. Oncology, Hormones, High Potent Drugs etc.)
Equipment (Design based on technologies adopted)
Slide 21 of 3021
Hetero Drugs Limited
Operational Challenges vis-à-vis Complexities of API Manufacture - Maintaining the Quality
Technologies
Others (Specifications/Process changes)
Skilled Manpower
Slide 22 of 3022
Hetero Drugs Limited
Operational Challenges vis-à-vis Complexities of API Manufacture - Maintaining the Quality
The Operations of the API Facilities need to be in sync with the changing dynamics, particularly w.r.t to the current Regulatory scenario, thus constantly upgrading within the limits of the Regulations, without affecting the Approval status of the Marketing Authorisations (of the Finished dosage manufacturer)
Slide 23 of 3023
Hetero Drugs Limited
Current Challenges
GDUFA – USFDA
Industry has already begun working on the plans to meet the requirements of the new regulation, starting October, 2013
Slide 24 of 3024
Hetero Drugs Limited
Current Challenges
New EU Directive for Importing APIs
The Industry is already in discussion with the Government of India in trying to find the right approach to meet the New regulations of European Authority